Osteogenesis Imperfecta
Dr Anton A.M. Franken Isala Zwolle
Dr. A.M
. Fran
ken
Osteogenesis Imperfecta (OI) brittle bone disease
• heterogeneous (clinical and genetic) group of inherited connective tissue syndromes characterized primarily by liability to fractures
• predominantly defect in biosynthesis of collagen type I
• prevalence 6-7 :100.000 • 17 genetic causes, 90% autosomal dominant • clinical classification of OI (type 1-5) • revised according Sillence (1979)
Dr. A.M
. Fran
ken
OI clinical diagnosis, nomenclature and severity assesment van Dijk , Sillence. Am J Med Genet 2014
OI syndrome name Type Gene Inheritance
Non-deforming OI with Blue Sclerae 1 COL1A1 COL1A2
AD AD
Common Variable OI with Normal Sclerae
4 COL1A1 COL1A2 WNT1 CRTAP PPIB SP7 PLS3
AD AD AD AR AR AR XL
OI with Calcification in Interosseous Membranes
5 IFITM5 AD
Progressively Deforming
3 COL1A1 COL1A2 BMP1 CREB3L1 CRTAP FKBP10 LEPRE1 PLOD2 PPIB SERPINF1 SERPINH1 TMEM38B WNT1
AD AD AR AR AR AR AR AR AR AR AR���AR AR
Perinatally lethal
2 COL1A1 COL1A2 CRTAP LEPRE1 PPIB
AD AD AR���AR AR
Dr. A.M
. Fran
ken
OI type I non-deforming OI with blue sclerae
• most frequent, mildest form, • autosomal dominant, COL1A1, 50% reduction
synthesis of type 1 procollagen • increased bone fragility with low bone mass • blue sclerae • deformity of long bones or spine uncommon • normal posture • hearing loss • dentinogenesis imperfecta (DI)
Dr. A.M
. Fran
ken
Dr. A.M
. Fran
ken
Dr. A.M
. Fran
ken
OI type II perinatally lethal OI syndromes
• prematurity, small for gestational age, perinatal lethality
• in utero fractures (rib), abnormal modeling, • Legs in frog position • skull severely undermineralized with open
fontanels • cardiopulmonal dysplasia • blue sclerae
Dr. A.M
. Fran
ken
OI type II
Dr. A.M
. Fran
ken
OI type III progressive deforming
• severe, non-lethal • multiple fractures (>100, also antenatal) • progressive deformity skeleton • short stature, scoliosis, • dentinogenesis imperfecta • respiratory insufficiency • wheelchair dependent • 11 genes both AD/AR
Michel Petrucciani
Dr. A.M
. Fran
ken
Dr. A.M
. Fran
ken
Dr. A.M
. Fran
ken
Dr. A.M
. Fran
ken
OI type IV common variable OI
• moderately severe • normal sclerae, short final stature • recurrent fractures • variable degree of deformity • dentinogenesi imperfecta • basilar impression (30%) • Inheritance: AD, AR, X-linked Dr. A
.M. F
ranke
n
Dr. A.M
. Fran
ken
Dr. A.M
. Fran
ken
OI type V OI with calcification in interosseous membranes
• moderate severe • normal sclerae, normal teeth • calcification inter-osseous membrane leads
restriction pronation ans supination • Specific bone histomorphometry • Inheritance : AD, IFITM5
• Overige typen
Dr. A.M
. Fran
ken
Dr. A.M
. Fran
ken
treatment
• Early and consistent rehabilitation intervention • fysiotherapy • ergotherapy • rehabilitation
• Orthopedic care
• Pharmacological treatment Dr. A.M
. Fran
ken
pharmacological treatment • Bisphosphonates:
– children: standard care: BP increase BMD and reduce fracture rate (Glorieux 1998 iv pamidronate; Gatti 2005 iv neridronate : Sakkers 2004 oral olpradonate, Bishop 2013, oral risedronate)
– Adults: BP increase BMD, no fracure rate reduction
• Teriparatide: – Adults: increas BMD, no data on fracture reduction
(Orwoll 2014)
Dr. A.M
. Fran
ken
Figure 1. Meta-analysis of placebo controlled trials of oral bisphosphonates in osteogenesis imperfecta
Hald JD, Evangelou E, Langdahl BL, Ralston SH (2014) Bisphosphonates for the prevention of fractures in Osteogenesis Imperfecta: Meta-analysis of placebo-controlled trials. Journal of Bone and Mineral Research Submitted:
Dr. A.M
. Fran
ken
pharmacological treatment • Bisphosphonates:
– children: standard care: BP increase BMD and reduce fracture rate (Glorieux 1998 iv pamidronate; Gatti 2005 iv neridronate : Sakkers 2004 oral olpradonate, Bishop 2013, oral risedronate)
– Adults: oral BP increase BMD, no fracure rate reduction
• Teriparatide: – Adults: increas BMD, no data on fracture reduction
(Orwoll 2014)
Dr. A.M
. Fran
ken
The Effect of Treatment with Teriparatide and Zoledronic acid in Patients with Osteogenesis
Imperfecta “TREAT-OI”
• Principal Investigator: Bente Lomholt Langdahl, Arhus DK.
Treatment The participants will be randomized to one of the following treatment regimens: Daily subcutaneous injections of placebo for two years and annual intravenous infusions of ZA 5 mg for 3 years. Daily subcutaneous injections of TPTD 20 µg for two years and annual intravenous infusions of placebo for two years followed by an intravenous infusion of zoledronic acid 5 mg in year 3. Daily subcutaneous injections of placebo for two years, and annual intravenous infusions of placebo for 3 years.
Primary endpoint: 1. Clinical fractures Secondary endpoints: 1. Bone mineral density (BMD) at the hip (femoral
neck and total hip) and lumbar spine 2. Bone structure assessed by QCT and HRpQCT 3. Bone turnover assessed by biochemical markers 4. Bone architecture and material properties evaluated
by histomorphometry and nanotechnology based techniques after treatment for 1 year.
Dr. A.M
. Fran
ken
Dutch OI-team
Children’s team (>250 patients) University Medical Centre Utrecht
Adult team (>230 patients) Isala Zwolle
Genetic diagnostics (>500 mutations) VU University Medical Centre Amsterdam
Meeting every 3 months
Dr. A.M
. Fran
ken
Multidisciplinary adult care one-stop-shop consultation
Basic team
• Orthopaedic surgery
• Rehabilitation medicine
• Internal medicine
• Physiotherapy/Ergo therapy
• Clinical genetics (Amsterdam)
Specialists “a la carte”
• Pulmonology
• Cardiology
• Neurology
• Radiology
• Gynaecology
• ENT
• Specialized dentist Dr. A.M
. Fran
ken
Adult OI expert centre Zwolle one-stop-shop consultation
• basic lab + vit D and bonemarkers • DNA analysis • Skeletal radiographs and DXA • Lung function test • Cardiac ultrasound • SF-36 questionaire Dr. A
.M. F
ranke
n
Database
• retrospective, cross-sectional explorative study in the first 149 adult OI patients
• demographics features • BMD • Total lifetime fractures • Fractures in relation to BP use
Dr. A.M
. Fran
ken
Cohort charatheristics
Dr. A.M
. Fran
ken
Table 1. Characteristics of the study population. Type OI I III IV Total patients 106 20 23
Fracture total Median, 1st quart – 3rd quart. (min-max)
15, 8-25 (0-100)
55, 36-100 (5-300)
20, 5-40 (0-51)
Total suffered fractures at the time of visit (% of all)
0-15
58.7%
10.5%
39.2%
16-25 17.3% 5.3% 21.7% 26-35 9.6% 5.3% 13% 36-45 3.8% 10.5% 8.7% >45 10.6% 68.4% 17.4%
Surgery necessary for at least 1 fracture (% of all)
88.2%
90%
94.4%
* In type III length/weight relations are disturbed and BMI is not useable. Dr. A.M
. Fran
ken
BMD
Significant difference in T-score between LS and HR in type I patiënts (p<0.001) and type IV patiënts (p<0.004)
Dr. A.M
. Fran
ken
Table 3. Z-Scores of all patients per type OI according to the WHO Classification. In percentages
(number of all)
Type I III IV DXA location
LS
(n=100)
HR
(n=106)
LS
(n=4)
HR
(n=5)
LS
(n=20)
HR
(n=19)
Normal Z-score ≥ -1.0
25%
(n=25)
54.6% (n=53)
-
20% (n=1)
20% (n=4)
42.1% (n=8)
Osteopenia -2.5 < Z-score < -1.0
41%
(n=41)
39.2% (n=38)
-
40% (n=2)
20% (n=8)
36.8% (n=7)
Osteoporosis Z-score ≤ -2.5
34%
(n=34)
6.2% (n=6)
100% (n=4)
40% (n=2)
40% (n=8)
21.2% (n=4)
LS= Lumbar Spine, HR=Hip Region
Dr. A.M
. Fran
ken
Total fractures at time of visit vs age
Dr. A.M
. Fran
ken
Table 4. Total suffered fractures at the time of visit (% of all patients). Type I patients who never (NEVER) used BP vs. patients who use BP
now or used BP in the past (EVER). Fracture total NEVER
(n=39) EVER (n=55)
0-15 64.1% 54.6% 16-25 17.9% 20% 26-35 10.3% 9.1% 36-45 2.6% 3.6% >45 5.1% 12.7% Dr. A
.M. F
ranke
n
fractures and BP use in type 1 patients
Dr. A.M
. Fran
ken
Discussion • BMD of adult OI patients varies greatly per measured
location bij DXA. BMD at LS is lower opposed to HR
• Adults with type I and IV there is low fracure rate. • Most fractures occur before adulthood
• In type III patients fracure total increases with age
• Half of type I and IV patients have never used BP • many patients which had used BP seem to have equal
fracture rates as patients which did not use BP
Dr. A.M
. Fran
ken
Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta
Ingo Grafe1 et al Nature Medicine june 2014
• TGF-beta: coordinator bone-remodeling by coupling osteoclast and osteoblast, modulates bioactivity of protoglycans in association with collagen fibrils
• TGF-ß produced by osteoblasts, secreted in in-active form and depositedinto bone matrix and activated during bone resorption
• OI :dysregulated/ excessieve TGF-Beta signaling both in recessive and dominant OI mouse models both in bone and lungs
• Anti-TGF-beta neutrallizing antibody treatment corrects the bone phenotype in both forms of OI and improves lungabnormaliteits
•
Dr. A.M
. Fran
ken
Dr. A.M
. Fran
ken
Dr. A.M
. Fran
ken